Korean J Hematol 2005; 40(2):
Published online June 30, 2005
https://doi.org/10.5045/kjh.2005.40.2.101
© The Korean Society of Hematology
박수정, 한치화
가톨릭대학교 의과대학 성모자애병원 혈액, 종양내과
Rituximab, anti-CD20 chimeric monoclonal antibody directed against the CD20 antigen on B lymphocytes, induces a targeted B lymphocytes depletion in the aim of eradicating autoreactive clones in various autoimmune disorders. Because of its biological properties, it has been used as a treatment option for a variety of autoimmune diseases. We report two complicated patients: a 26-year-old female with steroid induced Cushing's syndrome and avascular necrosis of both femur heads, and a 56-year-old female with multiple spine compression fractures due to osteoporosis, diabetes mellitus and cataracts. They had long lasting, more than 10 years, lupus-associated hemolytic anemia and Evans syndrome, refractory to corticosteroids and immunosuppressive agents. The patients were treated with Rituximab, 375mg/m2 once weekly for 3 consecutive weeks. They showed a remarkable recovery about 5th week and have been free of transfusion after the treatment with Rituximab. Therapy was well tolerated, and no infectious complications occurred. They are still in complete remission at 20 and 4 months following the treatment, respectively. We suggest that Rituximab can be a valuable agent in the management of autoimmune cytopenias refractory to standard treatments.
Keywords Rituximab, Anti-CD20, Autoimmune disease, Cytopenia
Korean J Hematol 2005; 40(2): 101-105
Published online June 30, 2005 https://doi.org/10.5045/kjh.2005.40.2.101
Copyright © The Korean Society of Hematology.
박수정, 한치화
가톨릭대학교 의과대학 성모자애병원 혈액, 종양내과
Soo Jeong Park, Chi Wha Han
Division of Hemato, Oncology, Department of Internal Medicine, Our Lady of Mercy Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
Rituximab, anti-CD20 chimeric monoclonal antibody directed against the CD20 antigen on B lymphocytes, induces a targeted B lymphocytes depletion in the aim of eradicating autoreactive clones in various autoimmune disorders. Because of its biological properties, it has been used as a treatment option for a variety of autoimmune diseases. We report two complicated patients: a 26-year-old female with steroid induced Cushing's syndrome and avascular necrosis of both femur heads, and a 56-year-old female with multiple spine compression fractures due to osteoporosis, diabetes mellitus and cataracts. They had long lasting, more than 10 years, lupus-associated hemolytic anemia and Evans syndrome, refractory to corticosteroids and immunosuppressive agents. The patients were treated with Rituximab, 375mg/m2 once weekly for 3 consecutive weeks. They showed a remarkable recovery about 5th week and have been free of transfusion after the treatment with Rituximab. Therapy was well tolerated, and no infectious complications occurred. They are still in complete remission at 20 and 4 months following the treatment, respectively. We suggest that Rituximab can be a valuable agent in the management of autoimmune cytopenias refractory to standard treatments.
Keywords: Rituximab, Anti-CD20, Autoimmune disease, Cytopenia
Sung-Eun Lee
Blood Res 2023; 58(S1): S13-S19Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang
Blood Res 2022; 57(S1): S37-S43Woojung Jeon, Young Kwon Koh, Sunghan Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(1): 41-50